PE Tech Report


Like this article?

Sign up to our free newsletter

BGF, Scottish National Investment Bank and Scottish Enterprise to invest £8m Elasmogen

Elasmogen – a biopharmaceutical company discovering and developing new therapeutics using its soloMERTM platform – has secured £8 million investment.

The funding round was led by BGF and Scottish National Investment Bank (The Bank), with additional support from existing investor Scottish Enterprise. 

The multi-million-pound investment will enable Aberdeen-based Elasmogen to continue developing its pipeline of next-generation drugs through pre-clinical trials.
The company’s soloMERTM technology is based on molecules naturally found in sharks’ immune systems, which are the equivalent of human antibodies but smaller and more stable. Elasmogen’s pipeline is focused on applying this soloMERTM technology to treatments of solid-tumour cancers, systemic inflammatory diseases and inflammatory conditions of the gut.

Like this article? Sign up to our free newsletter